Tianjin Medical University Cancer Institute and Hospital
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 and ≤ 75 years of age
Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer.
EGFR mutation testing negative of sensitive mutations
At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan)
Have failed for 1 lines of chemotherapy
ECOG performance scale 0 - 1.
Life expectancy of more than 3 months.
Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
More than 4 weeks after operation or radiotherapy
More than 4 weeks for cytotoxic agents
Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10\^9/L, neutrophils ≥ 1.5×10\^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min,
Signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.
You may not be if
Received more than one kind of chemotherapy regimens
NSCLC received other VEGFR inhibitors (except beacizumab) or docetaxel chemotherapy
Existing therapy related toxicity of prior chemotherapy and/or radiation therapy
Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure
Any factors that influence the usage of oral administration
The center of the tumor invaded local large blood vessels
Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3).
Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc.
Less than 4 weeks from the last clinical trial
Clareo Health | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
